Want to see GENB full AI Analyst Report?
GENB Stock Chart & Stats
$12.45
--
Market closed
$12.45
--
Day’s Range― - ―
52-Week Range$11.00 - $18.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.74B
Enterprise Value$1.72B
Total Cash (Recent Filing)$516.64M
Total Debt (Recent Filing)$65.57M
Price to Earnings (P/E)―
Beta0.52
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,192,490
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.03
Price to Sales (P/S)19.87
P/FCF Ratio-3.10
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue238.77
Enterprise Value/Gross Profit436.57
Enterprise Value/Ebitda-28.35
Forecast
1Y Price Target
$25.25Price Target Upside102.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-driven Protein Engineering PlatformGenerate's ML and computational protein engineering platform is a structural competitive advantage: it can accelerate candidate discovery, lower per-program R&D costs, and enable a diversified pipeline and partnerships across disease areas, supporting durable productivity gains.
Improving Revenue TrajectoryRevenue growth from $20.5M to $31.9M indicates emerging commercial traction or partnership/license progress. Sustained top-line expansion reduces reliance solely on capital raises and can support incremental reinvestment, improving long-term runway if growth persists.
Declining Absolute Debt LevelTotal debt declined year-over-year, showing some deleveraging. In absolute terms debt is moderate for a biotech at this stage, which preserves some financial flexibility and reduces near-term fixed obligations compared with rising debt trajectories.
Bears Say
Large And Worsening Cash BurnOperating cash flow deteriorated materially, and free cash flow is deeply negative. Persistent, growing cash burn is a structural risk that requires repeated financing, can dilute shareholders, and threatens continuity of R&D programs absent durable revenue or financing sources.
Widening Net Losses And Negative MarginsNet losses widened despite revenue gains, and margins remain deeply negative. That indicates operating costs far exceed revenues and that profitability is not yet structurally achievable without major cost reduction, new revenue streams, or radical scaling.
Deeply Negative Equity And Shrinking AssetsSeverely negative shareholders' equity and a large decline in total assets materially weaken balance-sheet flexibility. This structural impairment raises refinancing risk, constrains borrowing capacity, and limits strategic options during protracted cash burn.
GENB FAQ
What was Generate Biomedicines, Inc.’s price range in the past 12 months?
Generate Biomedicines, Inc. lowest stock price was $11.00 and its highest was $18.18 in the past 12 months.
What is Generate Biomedicines, Inc.’s market cap?
Generate Biomedicines, Inc.’s market cap is $1.74B.
When is Generate Biomedicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Generate Biomedicines, Inc.’s earnings last quarter?
Currently, no data Available
Is Generate Biomedicines, Inc. overvalued?
According to Wall Street analysts Generate Biomedicines, Inc.’s price is currently Undervalued.
Does Generate Biomedicines, Inc. pay dividends?
Generate Biomedicines, Inc. does not currently pay dividends.
What is Generate Biomedicines, Inc.’s EPS estimate?
Generate Biomedicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Generate Biomedicines, Inc. have?
Generate Biomedicines, Inc. has 128,192,490 shares outstanding.
What happened to Generate Biomedicines, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Generate Biomedicines, Inc.?
Currently, no hedge funds are holding shares in GENB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Generate Biomedicines, Inc. Stock Smart Score
Company Description
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
GENB Stock 12 Month Forecast
Average Price Target
$25.25
▲(102.81% Upside)
Ownership Overview
52.07% Insiders
<0.01% Mutual Funds
0.01% Other Institutional Investors
44.89% Public Companies and
Individual Investors